Information

Home Information
  • Dec 27, 2024

Morgan Stanley Sees Potential Growth in These 2 Surgical Robotic Stocks

In recent years, there has been a noted increase in the rates of chronic disease, as well as a growth in the number of surgical procedures. Let’s be clear: an increase in the incidence of chronic disease is a worrisome development. It does mean, however, that there will be a growing need for advances in the field of medical science as researchers look for new treatment options. That dynamic is part of the growth in surgical procedures, as new methods of surgical intervention come into use to tre

  • Dec 27, 2024

SEALSQ Corp Regains Nasdaq Compliance, Strengthening Market Position

SEALSQ Corp ( (LAES) ) has shared an announcement. SEALSQ Corp has regained compliance with Nasdaq’s minimum bid price requirement, securing its position on the stock market. This achievement reflects the company’s closing bid price of at least $1.00 for 10 consecutive business days, leading to the closure of the compliance matter by Nasdaq. This development is significant for SEALSQ as it maintains its market presence and reassures stakeholders of its stability and adherence to listing standard

  • Dec 27, 2024

Trump's first actions and job data to test market in January

NEW YORK (Reuters) -After closing the books on a banner year for U.S. stocks, investors expect to ride seasonal momentum into mid-January when a slew of economic data and a transition of power in Washington could send markets moving. The S&P 500 rose roughly 25% in 2024 through Dec. 27, while the technology-heavy Nasdaq Composite index <.IXIC >, which surpassed 20,000 for the first time in December, is up over 31%. "There are concerns that maybe the first part of (next) year can involve some repositioning and reallocation of funds and those that are trading today and next week are probably just trying to get a little bit ahead of that," said Robert Pavlik, senior portfolio manager at Dakota Wealth.

  • Dec 27, 2024

Ingles Markets Faces Nasdaq Filing Delay Due to Hurricane

Ingles Markets ( (IMKTA) ) has issued an announcement. Ingles Markets announced that it received a notice from Nasdaq due to a delay in filing its Annual Report for the fiscal year ending September 28, 2024. The delay, attributed to the impact of Hurricane Helene, has not affected the immediate Nasdaq listing of its Class A Common Stock. The company has until February 18, 2025, to comply with Nasdaq’s filing requirements or submit a compliance plan. Ingles Markets intends to file the report with

  • Dec 27, 2024

Elite Pharmaceuticals Launches Generic Vyvanse for ADHD Market

Elite Pharmaceuticals ( (ELTP) ) has issued an update. Elite Pharmaceuticals announced the launch of its generic version of Vyvanse® (Lisdexamfetamine Disylate) in various strengths, targeting the ADHD treatment market. The product, which is marketed under the Elite Laboratories, Inc. label, is expected to capture a portion of the $4.3 billion annual sales reported by IQVIA for the original product, potentially enhancing Elite’s market presence in the generic pharmaceutical industry. More about

Popular Post